MEREO BIOPHARMA GROUP PLC Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities of -GBP 8.25 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities · last filed 2023-03-28
| Period end | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 12 month | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 12 month as first filed |
|---|---|---|
| 2022-12-31 | -8.25M GBP 20-F · filed 2023-03-28 | |
| 2021-12-31 | -37.67M GBP 20-F · filed 2023-03-28 | |
| 2020-12-31 | 109.72M GBP 20-F · filed 2022-03-31 | |
| 2019-12-31 | -987.00K GBP 20-F · filed 2021-03-31 | |
| 2018-12-31 | -1.02M GBP 20-F · filed 2020-06-15 | -305.34K GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |